Open Banking Walked so Open Finance Could Run

Financial APIs are driving an overdue wave of innovation.

Over the last few years, open finance has become one of those vaguely defined fintech buzzwords. But with increasing regulatory movement in the US and nearly 70 million consumer accounts now interacting with financial APIs, it has become more relevant than ever.

Open finance has its roots in open banking, which refers to the use of application programming interfaces (APIs) to build applications fueled with consumer banking data. While largely invisible to consumers, open banking innovation has powered the novel ways that consumers now borrow, build wealth, and move money. The shift towards open banking has long been underway in the US and has paved the way for new open finance applications to flourish.

We define open finance similarly to open banking, but more broadly: the use of APIs to build applications that supplement consumer banking data with other information, defining users’ financial lives across their profiles of wealth, debt, insurance, sources of income, and more. The reason that open banking regulation is so exciting is that it’s the first step towards a world of open finance, where consumers can more fairly access financial products designed for their unique needs.

A Brief History of Open Finance

One might trace the origins of open banking in the US back to 1997, when Microsoft, Intuit, and CheckFree formed a combined open API standard known as the Open Financial Exchange (OFX). But open banking really started to catch on post-Great Financial Crisis when the US government enacted Dodd-Frank and created the Consumer Financial Protection Bureau (CFPB).

Now, after more than a decade, Section 1033 of Dodd-Frank — referring to consumers’ right to access their own financial data — has taken the main stage. In October 2023, the CFPB proposed the Personal Financial Data Rights rule. If it’s finalized in the fall of 2024 as anticipated, the rule would implement Section 1033 and codify open banking in the US.

The Rise of Financial APIs

A key driver in the adoption of open finance is the proliferation of financial APIs, and their superiority over earlier screen scraping technology. Drawbacks to screen scraping include connectivity issues any time a website experiences an update or outage, and heightened risk for financial institutions who are unaware who is scraping their consumer data and for what purpose. Instead, APIs dictate how systems can securely and efficiently exchange discrete data elements — and are the key enabling technology for open finance.

The adoption of APIs in financial services has accelerated over the last few years, as institutions have come to realize the heightened security, efficiency, and customer experience associated with them. At the same time, recent CFPB proposals are continuing to shepherd financial institutions toward a world of open APIs, enabling consumers to easily port financial data between providers. The Financial Data Exchange (FDX) emerged as an industry group whose open API standard incumbents and fintechs alike have rallied around. It is estimated that the FDX API now touches 65 million consumer accounts, up from 2 million just four years ago.

The Evolution of Bank Cooperation

The 2000s and 2010s saw a substantial debate over the right to access consumer financial data. At the time, data holders (namely banks and other incumbent institutions) cited IT costs imposed by data aggregators scraping their websites, while data users (like fintech applications) asserted that they were merely accessing consumer-permissioned personal data to better serve the end user.

Case in point: For several days in 2015, J.P. Morgan and Wells Fargo restricted customers of Mint (a then-popular, now-sunsetted account aggregator) from accessing their bank account information. Banks pointed to technical concerns such as data security and server capacity, though competitive threats loomed too. Even when institutions didn’t fully restrict access, they had other tactics at the ready: strict security standards, time-of-day restrictions, increasingly granular user permissioning, and costs for access.

Flash forward to today: Incumbents have come around to the promise of open finance as the technical advantages of APIs — and their customer experience improvements — have become more apparent. Disruptors and incumbents are increasingly collaborating here, too: members of the industry group FDX include a healthy mix of incumbents (like Bank of America and Wells Fargo) and disruptors (like Plaid and MX).

API technology, regulatory encouragement, and shifting consumer preferences are all fuelling a wave of new open finance startups. So what would it look like if the promise of open finance were fully realized?

Open Finance in Action

Many users already feel the benefits of linking their bank accounts with popular financial applications like VenmoCoinbase, and Robinhood via Plaid. However, at F-Prime we imagine that same level of data access expanding to other areas of a user’s financial life.

A large population of consumers still don’t have fair access to credit. Lenders can use payroll API solutions like Argyle to verify sources of income or solutions like Trigo to validate a customer’s ability to pay rent on time. Financial institutions can use Method to aggregate a consumer’s outstanding liabilities and reveal where they can refinance at a lower price, or employers can use it to offer debt repayment benefits to their employees. In the insurance space, Canopy Connect can help agents surface existing insurance policies and help potential customers dig for more competitive options.

This wave of consumer financial data aggregators will leave institutions and fintechs looking for an “aggregator of aggregators” solution, either routing between providers to maximize uptime or to paint a more accurate financial picture of the consumers they serve. Meld is one example. Others, like Prism and Pave, take consumer data via these APIs and produce financial insights in pursuit of a more modern and comprehensive credit score.

Looking Ahead

It will be a while before that vision becomes reality — 1033 is still directional sentiment, not regulatory action just yet. The proposed rule also only covers a subset of consumer financial accounts: deposit accounts, credit cards, and digital wallets. It says nothing about payroll data, for example. Meanwhile, the thousands of regional banks, credit unions, and other smaller financial institutions that make up the United States’ uniquely fragmented banking landscape will struggle to keep up with the required technological standards.

That said, in the long term we can see the growing array of consumer financial data APIs coming together to a holistic, real-time, and accurate financial identity for every consumer. Easy access to financial services and more tailored financial products will result. We are excited to see the institutional response to the new regulations and technology currently impacting the market — but we are much more excited about the effect that open finance will have on the end user experience for millions of Americans.

 

Originally published on Fintech Prime Time.

The 2024 State of Fintech Report

Assessing the industry’s rebound

For the fintech industry, it has been a wild couple of years. 2021 was a year of record-breaking valuations, revenue multiples, and VC funding. We then experienced an over-correction in 2022, with massive drops in valuations and multiples, and investors differentiating truly disruptive fintechs from those that merely provided a slightly better version of an existing financial service.

Access the full 2024 State of Fintech report here

The F-Prime Fintech Index reflected this rise and fall. In 2021, we measured public fintech companies’ market cap at $1.3T. By the time it found its floor the following year, the industry was worth $389B.

state of fintech

Now, heading into 2024, we see the fintech market in the midst of a rebound, with public valuations and multiples improving as investors prioritize profitable, sustainable growth. By the end of December, the F-Prime Fintech Index’s market cap stood at $573B. Overall, the Index rebounded 114 percent in 2023, and continues to outperform the S&P 500 by 540 percentage points. Revenue multiples have also made a modest recovery, though public investors are rewarding capital efficient growth and structurally attractive gross margins over revenue growth.

Correction Still Rippling Through Private Markets

While the public markets are in recovery mode, the over-correction of 2022 is still affecting private markets. We saw investment volume drop by around 50 percent last year to 1,639. However, it’s worth noting that more private investments were closed in 2023 than every year in history before 2019. Fintech has become one of the largest sectors in venture capital, and that is not changing.

Post-Series B valuations took the biggest hit in 2022 and while they climbed slightly in 2023, it is misleading because only the strongest companies raised in 2023. Those that could wait, did, and tried to grow into prior round valuations. 30-40 percent discounts in secondary trading are a leading indicator of 2024 valuations for some late-stage private companies.

state of fintech

2024 will be a tale of two cities, with high-performing companies continuing to raise without difficulty, while others struggle. Of the 819 companies that raised a Series A round in 2021, 43 percent — more than 350 — have not yet announced a Series B, acquisition, bridge round, or shutdown. Bridge rounds can only extend so far and most will need to raise or find a suitable landing in 2024.

 

M&A Activity Did Not Bounce Back

2023’s $98B in fintech M&A pales in comparison to 2021’s $349B. While we expected heightened activity from private equity and strategic buyers in 2023, the first half of 2023 was extremely quiet. High interest rates hampered PE borrowing patterns, scaled fintech companies lost their high multiple acquisition currency, and strategic acquirers were focused on reducing their operational expenses. The collapse of Silicon Valley Bank helped no one. However, the second half of 2023 M&A was brisk and portends a more vibrant 2024.

 

Reg On, Risk Off

Throughout the history of finance, waves of excessive risk-taking tend to usher in an era of regulatory scrutiny — think of the 1980s junk bond market and the 2008 financial crisis, for example. Having reached the “excessive risk” period in 2021, fintech has now entered a period of regulation.

Relationships between BaaS providers and charter banks are under scrutiny, as are private fund managers and retirement products that include cryptocurrency. Financial service providers are being urged to adopt risk management practices around its buy now, pay later products, and there is downward pressure on debit interchange fees. These are just some of the regulatory actions that impacted fintech this year — check out the report for a full list of the most important pieces of regulation we’re watching heading into 2024.

Reflecting on a Decade in Fintech Innovation

A decade into the fintech era, it is becoming clear where startups have disrupted existing financial services and where they were outmaneuvered or outlasted by incumbents.

Startup-led innovations like software-based payments (Stripe, Toast, Flywire), BNPL (Affirm, Klarna), and commission-free trading (Robinhood) genuinely disrupted incumbents and meaningfully shifted business models, revenue streams, and customer expectations. Elsewhere, incumbents embraced the very innovations startups introduced, leading to broad industry adoption more than disruption. For example, mobile banking and consumer-permissioned API access to financial data are now the norm.

In some sectors, incumbents “found innovation before startups found distribution.” For example, Betterment and Wealthfront pioneered robo-advisors, yet incumbents now control 80 percent of the market.

We should verbalize what you’re reading between the lines here: fintech startups have changed the industry in countless ways, but financial services incumbents are doing just fine. The top five banks have added $580B in market cap since 2003, and the top brokerages added $5.8T in client assets in the last five years.

Finally, the book is still being written for crypto, real-time payments, and GenAI.

 

Reasons for Continued Excitement

The industry is now operating at scale, with more than half of the 49 companies in the F-Prime Fintech Index posting over $1B in revenue in 2023. Yet these companies still only scratch the surface on their potential, capturing less than 10 percent of total US financial services revenue. There is still so much room to grow.

Even scaled fintechs — that billion dollar revenue club — are just getting started and growing an average of 45 percent annually, more than three times the rate of public incumbents. We expect the IPO window to open in 2024 for scaled fintech companies like Stripe, Klarna, Circle… and hopefully many more. We will add them to the F-Prime Fintech Index when they meet our published criteria.

 

Go deeper: Access the full report via the F-Prime Fintech Index here.

Behind the Breakthrough: Q&A with Peptone, Kamil Tamiola

Kamil Tamiola’s approach to better understand disease-causing proteins reflects his passion to study protein disorders.

Intrinsically disordered proteins (dubbed IDPs) and intrinsically disordered regions (IDRs) occur in one-third of the human proteome. Disordered proteins are shape-shifting and lack a consistent 3D structure. As a result, IDPs cannot be visualized using existing experimental methods, such as microscopy and mass spectrometry, or by predictive modeling approaches. Determined to “see” the invisible in the disordered proteome, Tamiola and his team have used interdisciplinary collaboration to address this longstanding challenge.

Tamiola had an opportunity early in his career to collaborate with researchers studying proteins implicated in progressive neurodegenerative disorders, like human alpha-synuclein and tau.

He explained, “It became evident that my expertise alone could only make a limited impact, and the true excitement lay in bringing together multiple disciplines.” The interdisciplinary collaboration was a significant shift for Tamiola, transitioning from solo physicist to cross-functional collaborator working closely with biologists and protein engineers. It was through this blending of different scientific disciplines that Peptone was born.

Peptone’s approach combines experimental and computational methods to study IDP molecular motions and their implications in biology. In a competitive landscape where some companies are using traditional approaches to tackle these challenging targets, Tamiola believes “Peptone’s technology can redefine what is considered “undruggable” into potential therapeutic opportunities.”

By leveraging proprietary tools to study protein shape and behavior before pursuing binding studies, Peptone can build more reliable models for drug discovery. This parallels the shift that X-ray crystallography brought to folded proteins, where understanding structure led to computer-aided molecule design.

What motivated you to start Peptone?

The idea stemmed from realizing the underexplored potential of IDPs while collaborating in academia.  Historically, drug discovery against disordered proteins involved screening, identifying binding molecules and then refining them through tools like NMR spectroscopy. With a bit of luck, we recognized how little effort had been devoted to this incredibly important class of proteins and set out to develop drug candidates that would bind to these proteins and exert a biological effect.

We began with some thrilling results that came out of proof-of-concept studies with pharmaceutical partners. We demonstrated the transformative power of using computers to alter the properties of disordered proteins and yield empirical results, all achieved without the existence of our own laboratory at the time.

These successful early endeavors motivated us to establish a dedicated laboratory, where we now engage in truly original research, and that was the moment that marked the inception of Peptone.


“It became evident that my expertise alone could only make a limited impact, and the true excitement lay in bringing together multiple disciplines.”

Dr. Kamil Tamiola, Founder & CEO, Peptone


Why is understanding the structure of intrinsically disordered proteins so important for advancing human health?

Intrinsically disordered proteins are widespread in the human proteome and across all life forms. They serve the purpose of enabling proteins to exhibit diverse, dynamic, and plastic structures to fulfill complex cellular functions. Unlike proteins with a singular function, these proteins collaborate with partners and can assume various structures. Considering the role of IDPs in numerous biological functions, both inside and outside the cell, there is a vast array of potential therapeutic targets.

IDPs are a large and diverse group and early research focused on neurodegeneration. This interest arose from the observation that bizarre, yet structured fibers found in human brains caused Alzheimer’s. Notably, the molecules forming these fibers lacked any inherent structure themselves.

Today, we recognize that in oncology, cardiology, autoimmune diseases, and even weight loss, disordered peptides play a crucial role – highlighting the broad relevance of disordered proteins across various therapeutic categories.

What makes you most hopeful about Peptone’s future?

We are seeing incredibly exciting data coming out of our programs and it is abundantly clear to us that this technology that we first developed for biologics research can also be successfully applied to small molecule drug discovery for intracellular targets.

As you read this, we are generating a wealth of data on challenging disordered targets showing great promise with clear therapeutic hypotheses. Our innovative insights position us to create best-in-class or first-in-class solutions. This is incredibly exciting as it allows us to revisit areas where people acknowledged the importance of a target but lacked a starting point. With Peptone’s unique approach and supporting data, we can now confidently guide progress.

How do think about the impact your early research can have on humankind overall?

I’m a humanist, and I believe in the value of humankind. And I still believe even with AI advances there will be a space and place and purpose for us in this world. Most importantly, I hope that companies like us, irrespective of how prolific we’ll be, will move the needle towards a better understanding of all these debilitating diseases and to giving people a better life.

What’s one lesson you’ve learned so far as CEO and founder?

Drug discovery is incredibly difficult with so many things that can go wrong. As much as we wish that we could reduce it to engineering and technological problems, I just don’t believe in that. What is incredibly humbling is the tremendous amount of artistry, devotion, and drive that individuals in the company must have, especially when there’s a challenge.

It is important to have a team that is motivated, almost obsessed with details, and in the face of setbacks, can find the inspiration to repeat experiments, look once again over data, and push in advance. So as CEO, my biggest responsibility is to communicate the progress of ups and downs transparently and concisely so we can make sensible decisions.

Who is someone who’s had the most professional impact on your career, and why?

I have two mentors. One is Dr. George Golumbeski and the other is Dr. Andrew Allen, both members of Peptone’s board of directors. Golumbeski is known in the drug discovery field as one of the most prolific deal makers who was key in the acquisition of Celgene by BMS. Andrew Allen is a professional chairman of our company but also an entrepreneur and clinician himself. They are both incredible people and play a vital role in shaping how I run the company and how I think about drug discovery. I call them my sounding board when it comes to decision-making, but also strategic thinking. Sometimes it is not even by giving me direct feedback, but by sending an article or a podcast saying, “Listen to this, look like these guys did it, what is there for us?” So, providing a learning experience in a variety of ways and I’m very, very grateful for that.

What’s one regular habit of yours that’s integral to your professional happiness and success?

Daily grand piano practice and reflection are very very useful. They really help me to calm down and focus and allow me to put myself in a sort of sensory deprivation mode to counteract all the stimuli I am exposed to daily. I’m also very committed to getting seven to eight hours of sleep every night and that is one thing I would recommend to anybody.

Subscribe to our newsletter to get the latest updates on how our portfolio companies continue to lead the way in their respective fields.

Fintech in Q4: The Return of BNPL and (Maybe) Crypto

Unpacking Fintech’s Q4 Rise

Fintech as a whole rose in Q4. Before we jump into the numbers, it’s worth highlighting a few notable stories hidden within them:

The Return of Buy Now, Pay Later: In the 11 months ending December 6, consumers spent $64.9B via BNPL platforms — a 15 percent jump from a year earlier. The markets reflect that rise, with BNPL provider Affirm’s revenue multiples tripling since Q4 2022. The company now trades at 11.2x. We have not seen that level of persistence for a publicly listed digital lender before — after all, Affirm has moved beyond B2C point-of-sale lending. On that note, in November the company announced that its partnership with Amazon had expanded to cover payments on its B2B store. Meanwhile, a surge in BNPL usage over Black Friday and Cyber Monday (up 20 percent on Black Friday and 42 percent on Cyber Monday) also lifted the company’s earnings.

Fellow BNPL provider Klarna is one of the top candidates to go public in 2024. But keep an eye on regulators, as the OCC recently issued a bulletin to help banks manage the risks associated with BNPL. For a deeper analysis on the vertical from an unapologetic BNPL evangelist, we enjoyed Simon Taylor’s “rant” earlier this month.

Crypto Spring?: Coinbase is currently trading at 15.1x, up from 1.3x in the depths of the crypto winter. That’s a stronger bounce than we’ve seen in cryptocurrency prices — Bitcoin has rebounded from $16,529 in December 2022 to $42,800 this month and Ethereum is now worth $2,562, up from $993 in July 2022. $4.6 billion changed hands on the new bitcoin ETF’s first day of trading — though the price has corrected post-launch and Vanguard did not join the likes of BlackRock, Grayscale, and Fidelity in launching a spot bitcoin ETF.

Shopify’s on a Roll: The e-commerce platform’s multiples have increased again QoQ and now trades at double its Q4 2022 multiple at 14.5x. What’s driving this growth?

  • After pulling the plug on its logistics side quest in May, the company has re-focused on its main game: building e-commerce stores for brands, adding enterprise clients, facilitating better omnichannel and mobile commerce experiences, and building its wholesale offerings.
  • That wholesale business is gaining traction, with B2B GMV up 61 percent in the first half of 2023. New customers include Kraft Heinz, Brooklinen, and Momofuko.
  • Shopify has been well-placed to harness the tailwinds propelling vertical SaaS. Across the fintech category, investors consistently reward vertical SaaS companies over other fintechs for their recurring revenue, high gross margins, and economies of scale.

And now, for those of you who love diving into the details on public stocks, we have:

 

The Q4 Numbers

LTM revenue multiples rose across the board in the last quarter of 2023, from 4.0x in Q3 to 4.8x in Q4. Multiples rose for all growth rates and verticals within the sector.

By Growth Rate:

Source: F-Prime Fintech Index

Companies that grew less than 20 percent (typically the larger companies in the Index) saw the biggest jump in Q4, almost doubling from 1.8x to 3.4x thanks to a broad recovery in market capitalization and enterprise value. The other two growth segments saw modest gains — find an interactive version of the chart above under “Historical Metrics” on the F-Prime Fintech Index.

By Vertical:

Source: F-Prime Fintech Index

Wealth and asset management saw the largest jump, with average multiples rising from 3.4x to 7.3x. Coinbase and (to a lesser extent) Robinhood drove the rise — see below.

Proptech companies collectively traded above 1x for the first time since Q2 2022, rising from 0.9x to 1.5x. Digital mortgage platform Blend drove the rise for the second quarter in a row.

 

Zooming In on WAM

Driven by rising equity and crypto prices, WAM companies’ assets under management and transaction volume have rebounded. The overall crypto market capitalization is up 62 percent to $1.3T since the beginning of 2023. Since the WAM sector is mainly a tale of two companies, let’s check in on the main players individually:

Net quarterly revenue for Coinbase was down six percent in Q3 to $623M, but still higher than the $576M 12 months earlier. The company is marching towards profitability on a GAAP basis, only losing $2M in Q3 2023.

However, those aforementioned gains in the value of crypto assets and a corresponding rise in trading volume mean that Coinbase’s Q3 numbers were less than impressive in light of trade-based revenues. In the third quarter, Coinbase generated $289M worth of trading revenue (down 21 percent year-on-year), with $275M (95 percent) coming from consumer activity and another $14M (5 percent) from institutional traders. Those figures were $310M and $17M respectively in the second quarter of 2023, and $346M and $20M a year ago. For now, Coinbase’s main growth comes via interest-based income (including interest earned on customer custodial funds and loans), as well as subscriptions and services like its stable coin arrangement with Circle and USDC.

Source: Reuters

Monthly active users over at Robinhood have been declining month over month, but it has compensated somewhat with steady increases in its earnings per client over the last six quarters. Similar to Coinbase, it has also seen its revenue boosted by rising interest rates, with income from interest surpassing transaction-based revenue for the first time in the company’s history.

Source: Reuters

Index Removals: Finally, while M&A activity continues to pick up in both public and private markets, no F-Prime Fintech Index companies were acquired this quarter. However, crypto trading platform Bakkt no longer met our criteria and was removed from the Index.


Written with Zoey Tang.

Building the Data Integration Layer for Wealth Management

Over the last ten years, investing in wealth management has become decidedly more exciting on the back of TikTok “finfluencers” and direct-to-consumer brands like Robinhood, Titan, and Public. An estimated $45B of venture capital flowed into wealth startups over the last decade, with B2C startups receiving 80% of late-stage capital raised. Robinhood almost singlehandedly disrupted $1.4B of retail brokerage commissions when incumbent brokerages matched Robinhood’s free stock trading (see F-Prime’s Wealth and Asset Management sector report for more).

However, gems are often found on the seemingly sleepier sides of markets, and we see some of the most exciting startups solving problems in the traditional world of financial advisors (aka WealthTech). At F-Prime Capital, we have had the opportunity to partner with the founders of exceptional WealthTech companies, including Quovo (acquired by Plaid), Vestwell, FutureAdvisor (acquired by BlackRock), and Canoe Intelligence. We are also thrilled to have just led the Seed round in Dispatch (fka OneAdvisory).

We wanted to share why we feel WealthTech is so interesting right now and why Dispatch has an opportunity to become a core part of the modern wealth management tech stack.

 

Why financial advisors?

Easy: that’s where the money is. Just over half of retail investable assets are managed by ~300,000 financial advisors. Second, it is an industry that only gets bigger. Advisor-led assets under management (AUM) has grown a steady 8-10% over the last 10 years; up from $17 trillion in 2013 to $34 trillion at the end of 2022.

ria industry growth

Why now?

The wealth management industry is experiencing a fundamental need for automation. While investing has become more automated over the last 10 years, most client-facing activities have not. Client onboarding, account opening, investment analysis, and reporting still involve an enormous amount of people and paper. We see four key drivers of automation, each presenting opportunities to rebuild the industry’s technology infrastructure.

Breakaway RIAs: Registered Investment Advisors represent the fastest-growing segment of wealth management. In 2022, nearly 1,300 advisors left traditional wirehouses (e.g., Morgan Stanley, Merrill Lynch, Wells Fargo, UBS) to follow the independent RIA route, taking an estimated $200 billion AUM with them. Alongside the breakaways, private equity is powering M&A across the industry – we estimate there were almost 1,000 RIA acquisitions in 2023. New RIAs want modern tech stacks (they are giving up those huge back-offices) and acquisitive RIAs want one modern tech stack, not one for each acquired firm. These trends require integration, digitization, and automation.

The rise of alternatives: Financial advisors were always a relevant channel for private equity, credit, and real estate funds; however, they are now the star of the show. Private funds need retail investors to continue growing, and financial advisors have embraced the idea of 25-30 percent allocations to private funds, substantially above the current five percent client average. It’s the perfect match, yet the infrastructure is missing. Client onboarding, capital calls, and reporting are all paper-based and advisors pay a high administrative price in exchange for the long-term commitment from their clients. We have written more here and here about the rise of alternative assets and the need for a new tech stack.

Generational wealth transfer: Financial advisors know they are on the verge of a stunning $70 trillion generational wealth transfer over the next 20 years. In anticipation, new wealth management firms like Titan and Facet are targeting those low-balance Millennials. While we expect both old and new firms to win their share, the one thing we know for certain is that Gen Y and Z want digital tools first, humans second. Most traditional wealth management firms will need major upgrades in their digital client onboarding, engagement, and reporting.

Artificial intelligence: We are just beginning to see AI extend into wealth management, but it is exciting to anticipate the impact it will have on client onboarding and servicing, as well as financial planning and advice. The combination of public and private LLMs can radically change the way clients interact with their advisors (and their chatbots). We wrote more about AI in financial advisory here.

 

Introducing Dispatch

Financial advisors recognize this need for automation, and numerous startups have emerged to address it. The typical financial advisor today uses 10 distinct financial advisory platforms, up from five just two years ago. The tech vendor landscape has truly exploded as well. As Jess Bost has noted, a picture is worth a thousand words:

ria tech stack

At this point, the solution has become a part of the problem. There are so many fragmented point solutions and duplicative sources of customer and investment data, that just maintaining data integrity and synchronization has added manual work and risk of errors. Client onboarding into ten separate tech platforms robs advisors of the very productivity they hoped to gain by adding a new tech tool. While an all-in-one tech platform could in theory solve these problems, that is simply not going to happen in an industry with a complex value chain (asset managers, advisors, custodians, servicers, et al.), all-in-one platforms built through M&A, and a highly fragmented advisor base.

The talented co-founders Rob Nance, Madalyn Armijo, and Rafi Lurie started Dispatch to address this fundamental problem of data management. Dispatch automatically (i) ingests client data from tax returns, financial statements, IDs, etc., (ii) enters it into advisor tech platforms, and (iii) perpetually maintains data synchronization across the advisor tech stack. Where a custodian offers API access, Dispatch will also automate account opening.

This is one of those deep infrastructure solutions that solves an enormous pain point, offers an immediate ROI, and can run in the background as the integration layer for customer data. The more integrations they support, the more valuable they become to the industry.

We have never been more excited to be investing in wealth management and feel fortunate to have partnered with Dispatch. The team thinks big, cares deeply, and executes relentlessly. The next few years are going to be great!

Providing the next generation of high-impact medicines

Biologics and peptides have revolutionized healthcare setting the stage for a new generation of equally transformative orally available small molecule medicines.

A critical gap in understanding GPCR biology has long held back an entire therapeutic category

G-protein coupled receptors (GPCRs) – a family of receptors that sense and respond to external signals – comprise the largest family of targets for approved drugs with 826 identified members, which represents approximately 475 drugs on the market acting on over 100 unique GPCRs. Abnormal GPCR activity has been directly linked to various chronic diseases including cardiovascular, metabolic, and pulmonary conditions. Despite the wealth of commercialized compounds, these proteins remain one of the most challenging target classes for structure-based drug discovery because advances in our overall knowledge of receptor structure and function have been relatively slow. As a result, more than 220 GPCRs have not yet been explored as clinical targets.

“Because the structure and function of biological macromolecules (i.e., proteins) are intimately intertwined, structural biology-based approaches offer an important foundation for drug discovery,” said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics. “Researchers have long sought out structural insights to gain intel about some of the most challenging targets (including GPCRs) across disease indications, and F-Prime shares in our commitment to developing differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies and provide better treatment options for patients everywhere.”

Small molecules are a category of medicine that offers substantial benefits such as their oral administration and design, which optimizes and targets distribution in the body. In addition, their potential for patient compliance is higher and they offer more flexibility than biologics.

One small discovery could pave the way to one large leap in medicine

Structure Therapeutics’ story began several years ago, when Professor Raymond Stevens’ research group at Scripps Research saw an opportunity to dive deeper into the science of GPCRs and the team’s foundational work was the successful initial reveal of the first human GPCR crystal structure bound to a diffusible ligand. This important discovery was followed by the characterization of other human GPCRs and coincided with over two decades of innovation in generating membrane protein structures with a focus on GPCRs to establish Structure Therapeutics.

While Structure can use its technology to develop drugs across a wide variety of GPCR targets, its initial programs focus on clinically validated targets to minimize biological risks. In addition, Structure believes that by offering small molecule drugs against targets where there are biologics administered as an injection, one can offer patients a more convenient alternative for much-needed medicines that can be dosed orally and cost less.

In only a few years from its founding in 2016, Structure Therapeutics successfully advanced two small molecule programs into clinical trials (GSBR-1290 and ANPA-0073) and one more in IND-enabling studies (LTSE-2578). The company raised $198 million privately before becoming one of biotech’s first initial public offerings in 2023. In addition, their lead program, the oral small molecule GLP-1 selective receptor agonist, has the potential to revolutionize the multiple billion-dollar obesity and diabetes market that is currently dominated by injectable and oral peptide drugs. F-Prime and Eight Roads had the foresight to know that GLP-1 was an increasingly important drug class.

The Structure Solution: Built for speed and efficiency

Learn more about how Structure’s approach can accelerate the lead optimization process, reduce development costs, and potentially increase the likelihood of clinical success compared to traditional drug discovery.

At the end of September, Structure announced positive results from the Phase 1b multiple ascending dose (MAD) study of its highly selective oral GLP-1 receptor agonist, GSBR-1290, in healthy overweight, or obese individuals. In the 28-day study, GSBR-1290 demonstrated significant weight loss supporting once-daily (QD) dosing and an encouraging safety and tolerability profile.

F-Prime acts locally to have an impact globally

At F-Prime, we help advance entirely novel technology platforms and therapeutic modalities by recognizing and furthering scientific breakthroughs. Structure was an attractive investment for F-Prime and Eight Roads from the very beginning and underscores how small molecule drug design is being transformed thanks to the explosion of cryo-EM and advances in computational chemistry.

The company created a global footprint early on, instituting its headquarters with business operations, finance, and clinical development in South San Francisco, and discovery and preclinical operations in Shanghai. This allowed the company to leverage the talent, resources, and infrastructure e.g., CROs available on both sides of the ocean. Working together with a global mindset, F-Prime’s Partners, Robert Weisskoff and Chong Xu helped to further guide the building of the company. Structure started with hiring, where F-Prime, together with Eight Roads, was key to recruiting their initial drug discovery and preclinical development leaders. The skilled group of drug developers, industry leaders, and scientific experts brought deep experience in understanding complex biological targets and mechanisms and had previously led the discovery, development, and commercialization of multiple successful drugs. The early discovery and preclinical efforts originally began in Shanghai and then followed in the U.S. with clinical activities as the company expanded its global operations. In addition, they facilitated the company’s business and financing – ultimately preparing the company for its public offering.

By empowering the next generation of companies as we did with Structure, we are proactively pioneering breakthrough science, novel technologies, and innovative platforms capable of addressing significant unmet medical needs.

 

“F-Prime shares our commitment to developing differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies and provide better treatment options for patients everywhere.”

—Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics

Future Of Financial Advice – More Co-Pilot Than Autopilot

When you put “wealth management” and “genAI” in the same sentence, most minds jump straight to some version of “autonomous finance.” However, that’s a concept that would have to overcome significant trust hurdles with advisors and the public to gain widespread adoption. According to research by Vanguard, the personal connection and trust that exists between financial advisors and consumers drives about 40 per cent of the value in any advisory service.

Over the last 10 years, advisors have started to transition from “stock pickers” to client relationship builders. As a result, new inefficiencies have emerged in the value chain: advisors now spend their time collecting and synthesizing information across a sprawling and outdated tech stack to help clients make decisions.

So, while generative AI isn’t going to put our money on autopilot any time soon, it has the potential to save advisors’ time by handling the more repetitive and labour-intensive aspects of their jobs. As a result, advisors will be free to build deeper relationships and trust with an expanding client base.

 

The current state of play
Most financial advisors juggle five different tech platforms every day:

ria tech stack investment advice

Many of the steps outlined above involve pulling together disparate information, often supported by different tech stacks, and synthesising it all to generate insights  a unique strength of generative AI technology is that it can quickly process large amounts of data.

 

Freeing financial advisors from mundanity
Generative AI will enable the construction of new “co-pilots” for financial advisors. Seeking to cut costs in an environment of fee compression, firms are eager to automate routine tasks. Those tasks include reviewing legal documents, opening accounts, preparing client presentations, adjusting asset allocation, requesting query service, addressing ad hoc questions, and other activities beyond their core role of advising clients, which currently take up 36 per cent of advisors’ time. Put another way: the average advisor spends more than two hours “behind the scenes” for every hour they spend with clients.

One way that CIO offices have attempted to streamline these processes is through the creation of in-house research databases. However, advisors still burn much of their workday conducting research, digesting information, and surfacing the most relevant insights in response to specific questions by their clients. It’s important to remember that most of those clients are seeking intuitive responses from a human they trust, rather than highly technical or precise answers.

Generative AI can swiftly perform the synthesising legwork for an advisor, who can then spend more face-to-face time with the client, create suggestions, and ponder implications for their personal portfolios.

Some incumbents (such as Morgan Stanley) are taking the time to build these solutions in-house. However, legacy tech debt means  that they usually take a long time to build – for example, Bank of America spent 10 years and $100 million to build its proprietary Merrill One Wealth Management platform. Others are understandably open to partnerships – see JP Morgan’s and TIFIN’s initiative to develop AI-enabled fintech companies. Meanwhile, startups such as Parcha envision a co-pilot that goes beyond answering questions and can instead complete tasks autonomously.

Many startups have built compelling AI-enabled products for advisors: Muse finds tax deductions and credits; Toggle assists advisors with investment research and addresses client questions based on the firm’s proprietary research; Greenlite and Parcha AI assist wealth management companies with KYC review and fraud reduction; and OneAdvisory is automating the collection of client data and account opening while maintaining data synchronisation across the advisor tech stack. In the past, companies such as DriveWealth helped fintech players build investment products for their end users. Going forward, we see a similar opportunity for API-based solutions that help fintechs build GenAI-enabled co-pilots for wealth managers.

Over the last five years, a few trends have emerged that create opportunities for GenAI-enabled wealth management solutions:

Growing data pools: The amount of data available to wealth advisors (from their internal systems, partners, third parties, and elsewhere) has significantly increased over the past decade. If advisors can quickly understand and harness this data they will be well-positioned to optimise financial planning for their clients, and offer tailored products and data-driven advice.

PE involvement: A wave of consolidation in the wealth management industry, with significant participation from private equity firms, would suggest an easier go-to-market path for startups by selling to a single decision maker who oversees many advisors. A GenAI solution that gives advisors more time to reach new customers would be an attractive tool in a PE firm’s search for cost-cutting and efficiency-boosting tools.

End-to-end options: We have also seen the emergence of end-to-end RIA tech stacks from companies like Farther Wealth, Zoe Financial, and Savvy Wealth. Financial data is currently fragmented across a broad advisor tech stack, which hampers the ability to take advantage of GenAI in this field. However, an end-to-end solution could create a proprietary data lake to effectively power GenAI tools. These platforms also have no legacy tech debt, reduce per-head-cost of growing an advisory business, and could therefore accelerate AI adoption in the industry.

Increasing budget share: Finally, wealth managers are spending more on software – an extra 10 per cent of wealth managers’ budgets have gone to third-party tech purchases since 2018, mainly to replace the industry’s 20-to-30 year-old existing stack. This means that advisors have cause and budget to seek out new solutions, and a wedge with generative AI could be a great catalyst to switch.

 

Implications for wealth management
While it’s still early, it is clear that generative AI will have a profound impact on the wealth management industry. Here are a few potential effects we see:

– Automated creation of individualised client summaries and tailored performance reports en masse, portfolio synthesis for advisors prior to client meetings, and much more – all powered by GenAI;

– With more time on their hands, advisors will expend more effort on deepening and expanding their client base. Co-pilots will also cut the cost of service delivery, reduce the duration of client meetings, and make room for more self-serve and bespoke services;

– By allowing fewer advisors to serve more customers, AI-enabled tools should also expand margins for the larger companies in the F-Prime Fintech Index over time. Meanwhile, GenAI would expand the capabilities for the industry’s best wealth managers, allowing them to win significant market share. However, poor-performing managers may lose clients as they flock to high performers with increased capacity;  and

– Finally, as the cost of advisory services decrease, financial advice will continue on a trend of democratisation.

In 2022, we released a report highlighting the trends affecting the wealth and asset management sector. When we release our next report, we expect generative AI will have planted seed across the advisor value chain.

 

This story originally appeared in WealthBriefing.

A Venture Capitalist’s Perspective on Robotics

robotics investment

Despite the expectations of past science fiction writers, robots are still far from common in our everyday lives, notes the venture capitalist community. More than a fifth of the 21st century has now passed, and the worlds of The Jetsons and Lost in Space still feel like projections of a distant future.

However, away from the domestic lives that most of us inhabit daily, robots have suddenly become pervasive in some industries. Self-driving cars are moving from research labs to the road, Boston Dynamics continues to release incredible video demos — and many investors are starting to take notice.

What has changed to drive this acceleration in both the technological capability and deployment of robotics? Venture capitalists see three key factors:

1. Labor costs continue to rise and are now 45% above 2000 levels.
2. The cost of robotics components has dropped, so innovators can piece together existing platforms and spend more time focusing on the truly groundbreaking elements of their technology. For example, the cost of a robotic arm has fallen 90% since 2000. In business speak, this means nobody has to “reinvent the wheel” every time they want to build a new robotics solution.
3. Software has advanced to the point that it can support robotics technology with complex tasks, buoyed by a 400% increase in AI investment over the past five years.

 

Where the Money is Flowing

The robotics space changes rapidly, with constantly rotating “hot sectors,” tweaks to business models, and shifting investment and exit dynamics. To better understand the industry landscape, F-Prime Capital recently completed a comprehensive analysis of more than 1,250 robotics companies that raised funding over the past five years.

In the resulting report, we found that $90 billion worth of funding had gone to the robotics industry since 2018, representing roughly 10% of overall investments in tech.

vertical robotics

We identified three main categories for robotics investment:

Autonomous vehicles — public roads only

Vertical robotics — use-case specific and mostly focused on industrial settings

Enabling systems — hardware and software components that others can use to build complete solutions

Autonomous vehicles (AVs) accounted for more than 50% of robotics funding in most years. However, as investors began to question the paths to commercialization for many companies in the sector, AVs saw a stark decline in 2022.

Vertical robotics companies now take the majority of venture funding available for robotics technology. Within this, logistics, defense, medical, and manufacturing applications tend to attract the most investment capital.

However, as we’ll discuss below, the fall in investment that began in 2022 is on track to continue through 2023.

early robotics unicorns av lidar

Another way to trace this shift in focus from AV to vertical robotics is to observe the types of unicorns that have emerged in the space. The 2018 and 2019 crops of robotics unicorns clustered in the AV and enabling lidar space — several of which have since shut down — while the 2021 and 2022 crops tend to center around vertical robotics.

This year has been challenging for startup fundraising, and robotics is no different. The first half of 2023 saw investments decline more than 50% relative to 2022, which itself was down 30% from the heights of 2021.

Fortunately, the second half of 2023 is looking more promising, with several high-profile funding rounds for companies like Anduril, Aurora, and Stack AV.

deal count in robotics

A deeper dive into the funding environment, however, shows a wide range of behavior by stage. Early-stage deals have shown a relatively modest decline in 2023, whereas mid- and late-stage deals have been far more challenging. This is largely attributable to overvalued earlier-stage companies that raised at the height of the market, which are now facing valuation expectation mismatches when they re-engage investors for their next round of funding.

The exit environment has also created challenges for robotics startups. IPOs and SPACs have ground to a halt in the past 18 months, while mergers and acquisitions are down 50% since 2021.

However, even in the best of times, the vast majority of M&A deals since 2018 have been worth less than $250 million, with only a handful of notable exits. Among them: Auris’ $5.75 billion acquisition by Johnson & Johnson in 2019, and Uber ATG’s acquisition by Aurora for $4 billion in 2020.

Public market performance has also been mixed, with robotics companies that have built scaled, high-growth businesses faring best — Symbotic, AutoStore, PROCEPT Biorobotics, and Hesai Technology are the standouts here. For others, valuations have significantly reset.

exits m&a in robotics

 

What’s next for venture capital and robotics?

The boom in autonomous vehicle investment catalyzed a new generation of robotics entrepreneurs and engineers. They are now using that know-how to build startups that solve real customer pain points.

As venture capitalists, we believe the industry remains in its early innings. Indeed, the exit environment is still maturing, and hardware businesses still face an additional layer of complexity compared to pure software businesses.

But for those with experience in the industry — and who understand its unique metrics and business models — it is clear that opportunity is growing at an accelerated rate.

Founders should be aware the era of exiting a business based on little more than “promising technology” is over — you must eventually build a real business. Tech demos do not equal commercial success, and investors have wised up to the fact that production deployments delivering measurable ROI trump pilot customers who are “excited by the technology” every time.

As demonstrated by the data outlined above, it’s also important to note that, for now, capital remains scarce. Founders must build capital-efficient businesses to entice investors. For many, capital efficiency, or a lack thereof,  can make or break a founder’s pitch.

Today’s robotics founders have several tailwinds at their back: technological acceleration, labor shortages, stagnant productivity gains, and a cadre of investors who are increasingly interested in the category. Those who can learn the hard-fought lessons of the past five years — including the experience of AV companies and the macro rise and fall in tech investment dollars — are well-placed to find success in this unique category.

 

Originally published in The Robot Report

Check out the full State of Robotics report here. 

Behind the Breakthrough: Q&A with Lyn Baranowski, Avalyn Pharma

“It was really striking to me how little research and development was going on despite how serious these diseases are. Many of them are deadly, and patients have very few treatment options. I thought that there was a lot of good that I could do personally to try to bring some new treatments to market.”

There are more than 200 types of Interstitial Lung Diseases (ILD), and the most severe cases, which include Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), have a patient survival time closer to 3-5 years from diagnosis without a lung transplant. The disease severity is what sets the life expectancy apart for IPF and PPF and currently approved therapeutics for these respiratory illnesses can slow disease progression but carry significant side effects that limit their use. Baranowski saw an opportunity to address a large unmet need and eventually made her way to Avalyn Pharma, which was built on the mission to develop inhalable medicines that minimize systemic exposure and are more precisely targeted to the lungs. She feels she can have the most impact serving in roles at smaller companies, where “you can really see and feel the outcome of your day and how you spend time in terms of driving the company forward.”

On the heels of Avalyn’s tremendous success with an oversubscribed $175 million Series C financing in September, Baranowski shares more about her background, leading and advancing Avalyn, and insights into her leadership style.

What motivated you to join Avalyn Pharma?

My career began at Novartis, where I primarily focused on the commercial, financial, and strategic aspects of the business. It was there that I was exposed to the significant unmet needs in lung diseases, particularly in rare conditions like pulmonary fibrosis, cystic fibrosis, and pulmonary hypertension. I observed the lack of research and development in these areas and recognized the severity of these diseases, often with limited treatment options.

Driven by a desire to make a positive impact, I left Novartis to work at a New York family office involved in venture capital-style investing. My biggest investment in those years was in Pearl Therapeutics, a company working on combination therapies for asthma and COPD. This experience provided valuable insights into inhalation drug delivery.

Over the years, I discovered my passion for working in smaller companies, building teams, drug pipelines, and making a difference. Despite limited resources, I found it rewarding to be entrepreneurial and witness the tangible impact of our efforts. I was heavily involved in the respiratory therapeutic area which is why my passion for addressing rare lung diseases continues to grow and I’m excited about the potential to make a positive impact in this field.

What differentiates Avalyn from other IPF and ILD players in the industry?

Most lung-focused companies still prioritize systemic drug delivery and in the case of IPF, inhaled delivery is a distinctive approach. At Avalyn, we focus on pulmonary fibrosis, a deadly disease that falls under the umbrella of interstitial lung diseases, and despite its severity, there are only two approved drugs for this condition, pirfenidone and nintedanib, both of which are administered orally. These oral medications are often poorly tolerated, leading to a high rate of discontinuation, with only 30% of patients in the U.S. taking them.

Our therapeutic focus is to improve treatment by delivering these drugs through inhalation. This approach enhances drug concentration in the lungs, improving clinical efficacy, while reducing systemic exposure, resulting in better tolerability. Inhaled delivery is itself incredibly challenging and complicated, so you really have to think about the way to deliver the medicine, how often you deliver the medicine, what the formulation is, and what the device is. It has the potential to make effective drugs more accessible and tolerable for patients, potentially extending their lives and improving their overall health. This shift in perspective is a learning curve for our field, and we hope the market will follow suit, positioning us for future success.

Avalyn’s executive leadership team and board of directors is 50% women. What’s that like, and how does it compare to the industry as a whole?

Are there any companies in our industry whose board is half women? I don’t think so. I’m incredibly proud of that. We’ve also just hired a bunch of fabulous women who aren’t necessarily on our leadership team but are VP-level. I care about hiring people who care about their jobs and patients, and I think that’s again, the right way to align as a team and be motivated.

What advice would you give to the next generation of female leaders?

Do not shy away from being empathetic. As a woman, it is important to remain committed to embracing this part of our identity. I believe in being authentic and accept that it’s perfectly fine for me to get a little emotional when a patient shares their story with us. Making a difference for patients is what drives me and I’m often touched by the stories they share with us about what living with their disease is like.  It’s a natural and genuine response, and I’m proud of it.

What’s been the most rewarding part since joining Avalyn in 2022?

I love telling the story of the company, so it’s a lot of fun for me to sit down with doctors,  investors, analysts, or people we’ve recently hired at Avalyn and tell them what we’re up to. It’s empowering to watch people go from not fully understanding to a moment of excitement and realization of the impact we can have.

We also just completed a $175 million financing at the end of September which feels like a huge accomplishment, especially in today’s market, and has enabled me to start hiring great people.  Whether it is people that I’ve worked with before or have always wanted to work with, it feels great to now have an incredible team that we’re building and together, we’re going to do a lot of good for a lot of patients. At the end of the day, 95% of the fun I have at work has to do with the people I work with and how much I enjoy working with them.

What’s one lesson you’ve learned so far as CEO?

Don’t be afraid to be passionate and be yourself. I’m genuinely passionate about what I’m working on, and I know it translates to my peers because I’ve been told it’s infectious. If you can do that and lean into what you’re good at, then people respond to it. And, if you don’t know the answer, that’s okay. Ask your colleagues for help, advice, and feedback.

How has F-Prime been supportive during your tenure as CEO?

When I started at Avalyn a year ago, F-Prime’s Ketan Patel and Brian Yordy were invaluable and provided me with essential context regarding our historical data and the market’s overarching trends. They both possess a unique perspective when interpreting data, which enriched my own understanding and enhanced my capabilities.

How would you describe your leadership style?

I am very much a lead by example kind of person. I love talking things through and collaborating and getting people’s input. If I have a strong opinion, I’ll tell you, but often I like to hear from the team, and I think people like to be heard. At Avalyn, we’re all about integrity and keeping the patients that we’re trying to serve at the center of our focus. To me, that’s the right thing to do, but it is also the right thing for our business. If we can make decisions about how to develop our drugs with patients in mind, it means we bring drugs to market that are going to be able to impact their lives positively.

At the end of the day, we all work in this industry because we care about making a difference in patients’ lives and if we can keep that as our driver and our mission, it’s a great way to remind people of why we all wake up in the morning and what we’re trying to do together.

What makes you most hopeful about Avalyn’s future on the heels of a successful series C fundraise?

We’re in the process of launching a significant clinical trial for inhaled pirfenidone (AP01), and our focus is on diligently executing the study startup. This trial is set to be a large, well-controlled global effort, representing a crucial step forward for inhaled pirfenidone’s path to market, which is a very exciting development.

The capital we just raised also allows us to do the next stage of work with AP02 (inhaled nintedanib), which is the second lead clinical asset, and continue our efforts on the preclinical work for the fixed-dose combo of the two together. By transitioning from one mechanism to two, this combination therapy has the potential to revolutionize our field.

A lot of exciting initiatives are going on and it is my priority to build the company, grow the team, and do all the important work to set us up for success for the next stage.

Subscribe to our newsletter to get the latest updates on how our portfolio companies continue to lead the way in their respective fields.

Software Buying Has Changed Forever

Software buyers are now more sophisticated than ever. In an early age of software sales, suited-and-booted Oracle salespeople were taking buyers out to dinner and educating them about a solution while engaging in a formal discovery and RFP process. It was an excessive and long sales cycle, with buyers learning about a product and building a trusted relationship with a small number of sellers. This formal dance led to a mediocre problem-solution fit, no concept of after-sale customer success — and still came with a big-ticket price tag.

Today, buyers are far more savvy and educated software purchasers, and range from CIOs to departmental teams. They know the right questions to ask and if they don’t, formal and informal networks exist for virtually every job function — from CISO slack channels to engineering manager meetups to conferences for finance heads and HR leaders. Public forums like G2 Crowd and Capterra have digitized formal review services (which now include feedback from peers as well as experts) while data-driven buyer intelligence platforms like Vendr support the full procurement lifecycle.

Buyers now come to vendors already understanding their needs and how it will work with their tech stack, and it’s very likely they already know which solution is best for them. With hundreds of B2B SaaS companies in our global portfolio, we have had a front-row seat as these interactions between reps and prospects changed over time, and this market transparency has been an incredible forcing function for software vendors to step up their game — from product to sales to customer success and beyond. And as a result, the existing tools of managing customer engagement are no longer sufficient. Software vendors and their sales and marketing teams need solutions that help them engage with better-educated customers at precisely the moments customers want that interaction.

Enter Warmly, which is building the world’s first AI-driven, autonomous sales orchestration solution to help software vendors thrive in this digitally-enabled, fast moving environment. Warmly intelligently alerts sales and marketing reps when a potential customer engages across channels, complete with context about the prospect’s role and network. Warmly automatically sends intent-based outreach on behalf of the sales team, which frees time for higher value activities like building relationships with customers or personalizing messaging. It allows sales teams to scalably interact with prospects in a way that is productive and personalized for both parties. We believe Warmly can be a foundational solution for this type of event-driven sales future.

Congrats to founders Maximus Greenwald, Carina Boo, Alan Zhao, and the visionary team at Warmly on their $11M Series A funding from Felicis, NFX, Zoom Ventures, Maven, and F-Prime Capital.